CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Genome-editing involves the insertion, deletion, or replacement of DNA in the genome of a living organism using "molecular scissors." Traditional genome editing with engineered nucleases for human stem cells is limited by its low efficiency, high cost, and poor specificity. The CRISPR system has recently emerged as a powerful gene manipulation technique with advantages of high editing efficiency and low cost. Although this technique offers huge potential for gene manipulation in various organisms ranging from prokaryotes to higher mammals, there remain many challenges in human stem cell research. In this review, we highlight the basic biology and application of the CRISPR/Cas9 system in current human stem cell research, discuss its advantages and challenges, and debate the future prospects for human stem cells in regenerative medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 1×
“It nonetheless retains the capacity to generate the gRNA/Cas9 complex for binding with the targeted DNA regions.(17) Kearns et al.”
BackgroundDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299 · cited 5×
“Cas9 nickase (Cas9n) is a mutant version of Cas9 that generates just a nick on the gRNA-bound strand without breaking the whole double-strand DNA.95 This system needs a pair of gRNAs to form two gRNA/Cas9n complexes for DNA cleavage and can dramatically decrease the off-target in human ESCs.96 Kleinstiver et al.97,98…”
BackgroundInfluentialSelf-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“, RNG) can also lead to being off-target.(80,81) The ratio of being off-target is relative to the targeted genes and hosts.”
BackgroundGenetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“Fu et al.(99) reduced off-targets 5,000-fold by using truncated gRNAs.”
BackgroundKim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 2×
“Eyquem et al.78 engineered T cells to express CAR uniformly by directly fusing CD19 CAR to cells’ TRAC gene and also increased their potency.”
BackgroundSelf-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596 · cited 1×
“It is now possible to easily and rapidly create a specific marker by fusing epitope tags or fluorescent proteins to the genes of interest.(31,32)With the exception of NHEJ, homology-directed repair (HDR) is another mechanism by which exogenous nucleotide sequences can be introduced into the genome through homologous r…”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“This was sufficient for cell transplantation and avoided the difficulties caused by random integration in lentivirus or retrovirusmeditated gene therapy.(60,61) CRISPR/Cas9-mediated gene correction has become a principal therapeutic strategy in the study of genetic diseases such as b-thalassemia, Duchenne muscular dys…”
BackgroundSchwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424 · cited 4×
“Their pluripotency can be sustained well under 3D culture conditions when screening the targeted colonies.(50) This strategy has been proposed as a new platform for cancer research.”
BackgroundInfluentialXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“We can easily obtain extremely high titering AAV virus using helper plasmids during virus packaging with consequent higher infection efficiency than lentivirus.(138,139) More importantly, an AAV-delivered donor is genome integration-free.”
MethodCRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo
Moreno-Mateos, M. A., Vejnar, C. E., Beaudoin, J.-D., Fernandez, J. P., Mis, E. K., Khokha, M. K., & Giraldez, A. J. (2015) · Nature Methods · doi:10.1038/nmeth.3543 · Cited by 1,290
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137 · cited 6×
“It is almost impossible for some stem cells, such as HSCs and MSCs, to be expanded sufficiently for clinical application from screening a single cell after the manipulation of CRISPR/Cas9.”
MethodInfluentialModeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids
Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., & Sato, T. (2015) · Nature Medicine · doi:10.1038/nm.3802 · Cited by 1,135 · cited 2×
“Matano et al.51 engineered normal human intestinal organoids by knocking out several tumor suppressor genes and oncogenes simultaneously, and showed formation of tumors following subcapsular injection into the kidney.”
BackgroundChemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090 · cited 2×
“Hendel et al.(111) utilized some chemical groups to protect the phosphoramidites of gRNAs and significantly enhanced the genome-editing efficiency of CRISPR/Cas9 in T cells and CD34 HSCs.”
BackgroundSequential cancer mutations in cultured human intestinal stem cells
Drost, J., van Jaarsveld, R. H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., Sachs, N., Overmeer, R. M., Offerhaus, G. J., Begthel, H., et al. (2015) · Nature · doi:10.1038/nature14415 · Cited by 1,067 · cited 2×
“Similarly, Drost et al.(52) produced the most common mutant genes in intestinal organoids to reveal the functions of APC and P53 genes in intestinal neoplasia.”
BackgroundIn vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046 · cited 2×
“It permanently exists as episomal DNA in cells and largely promotes efficiency of CRISPR/Cas9-mediated gene correction in stem cell therapy.140–142 For example, Tabebordbar et al.143 repaired mutant Dmd genes by AAV-delivered CRISPR/Cas9 in muscle stem cells.”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“In addition, the immunogenicity of AAV remains another risk that must be considered.(146)”
BackgroundDimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing
Tsai, S. Q., Wyvekens, N., Khayter, C., Foden, J. A., Thapar, V., Reyon, D., Goodwin, M. J., Aryee, M. J., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2908 · Cited by 952
Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells
Wu, X., Scott, D. A., Kriz, A. J., Chiu, A. C., Hsu, P. D., Dadon, D. B., Cheng, A. W., Trevino, A. E., Konermann, S., Chen, S., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2889 · Cited by 944 · cited 1×
“Wu et al.(84) revealed that off-target sites were mainly related to genes in mouse ESCs.”
BackgroundYin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757 · cited 1×
“CRISPR/Cas9 can be used to increase their anti-tumor efficacy by disrupting the programmed death protein 1 (PD-1) in CAR T cells by eliminating PD-L1 (PD-1 ligand) expressed tumor xenografts in vivo.(77) In addition, CRISPR/Cas9 can be utilized to eliminate the risks associated with lentivirus-mediated CAR T cells, su…”
BackgroundThe retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738 · cited 1×
“Rb1 is known to initiate retinoblastoma in humans.(39) RB1 null human ESCs generated by CRISPR/Cas9 showed aberrant mitochondria and were shown by drug screening to be sensitive to”
BackgroundHigh-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells
Zhou, Y., Zhu, S., Cai, C., Yuan, P., Li, C., Huang, Y., & Wei, W. (2014) · Nature · doi:10.1038/nature13166 · Cited by 733
Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells
Kleinstiver, B. P., Tsai, S. Q., Prew, M. S., Nguyen, N. T., Welch, M. M., Lopez, J. M., McCaw, Z. R., Aryee, M. J., & Joung, J. K. (2016) · Nature Biotechnology · doi:10.1038/nbt.3620 · Cited by 670
Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H. (2014) · Genome Research · doi:10.1101/gr.171264.113 · Cited by 655 · cited 2×
“Gene manipulation can be easily achieved by transient transfections of gRNA/Cas9 nuclease-expressed plasmids or their purified synthetic products in common cells.(7,8,107,121) The situation becomes more complex in stem cell studies as stem cells are more fragile, sensitive, or resistant to the transient delivery metho…”
BackgroundMethodHomology-directed repair is a major double-strand break repair pathway in mammalian cells
Liang, F., Han, M., Romanienko, P. J., & Jasin, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5172 · Cited by 649 · cited 1×
“9 December 2017 at a cell level.(9,34) For stem cell differentiation, Adkar et al.”
BackgroundHighly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair
Auer, T. O., Duroure, K., De Cian, A., Concordet, J.-P., & Del Bene, F. (2014) · Genome Research · doi:10.1101/gr.161638.113 · Cited by 631
Sequence determinants of improved CRISPR sgRNA design
Xu, H., Xiao, T., Chen, C.-H., Li, W., Meyer, C. A., Wu, Q., Wu, D., Cong, L., Zhang, F., Liu, J. S., et al. (2015) · Genome Research · doi:10.1101/gr.191452.115 · Cited by 625
Correction of a genetic disease in mouse via use of CRISPR-Cas9
Wu, Y., Liang, D., Wang, Y., Bai, M., Tang, W., Bao, S., Yan, Z., Li, D., & Li, J. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.10.016 · Cited by 614
CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity
Cradick, T. J., Fine, E. J., Antico, C. J., & Bao, G. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt714 · Cited by 590 · cited 2×
“Some studies have shown that shorter gRNAs can reduce the occurrence of offtarget by reducing their mispairing with the targeted genome, but the indels of on-target will also decrease accordingly, because binding of shorter gRNAs to the targeted genome is not as stable as that of longer ones.(82,83)”
BackgroundA dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556 · cited 1×
“This may induce undesired genome damage and ultimately lead to cell death.(145) Although this situation has been resolved by delivering donor (AAV) and CRISPR/Cas9 (transient delivery strategies) separately, the advantages of AAV are partly concealed.”
BackgroundA Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging
Zhang, W., Li, J., Suzuki, K., Qu, J., Wang, P., Zhou, J., Liu, X., Ren, R., Xu, X., Ocampo, A., et al. (2015) · Science · doi:10.1126/science.aaa1356 · Cited by 551
CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs
Mandegar, M. A., Huebsch, N., Frolov, E. B., Shin, E., Truong, A., Olvera, M. P., Chan, A. H., Miyaoka, Y., Holmes, K., Spencer, C. I., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.01.022 · Cited by 525 · cited 2×
“Mandegar et al.19 fused a doxycycline-inducible dCas9 with KRAB and achieved conditional and reversible interference in human induced PSCs (iPSCs) and its derived somatic cells such as cardiac progenitors, cardiomyocytes, and T lymphocytes.”
BackgroundEfficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475 · cited 1×
“Use of the CRISPR/cas9 system has enabled many genes in HSCs to be successfully manipulated.(46) Unfortunately, difficulties persist in the maintenance of these gene-manipulated HSCs during selection, purification, and expansion.”
MethodVeres, A., Gosis, B. S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C. A., Talkowski, M. E., & Musunuru, K. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.020 · Cited by 474
Small molecules enhance CRISPR genome editing in pluripotent stem cells
Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.003 · Cited by 455
Self-citationA Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks
Parnas, O., Jovanovic, M., Eisenhaure, T. M., Herbst, R. H., Dixit, A., Ye, C. J., Przybylski, D., Platt, R. J., Tirosh, I., Sanjana, N. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.059 · Cited by 440
Xie, F., Ye, L., Chang, J. C., Beyer, A. I., Wang, J., Muench, M. O., & Kan, Y. W. (2014) · Genome Research · doi:10.1101/gr.173427.114 · Cited by 408 · cited 3×
“Millions of cells can be handled in one reaction based on electroporation; nonetheless, much time and effort have been expended in purifying the real transfected cells using selection cassettes.(58,124) Lipidosome reagents are not as popular as the other three methods for human stem cell transfection, because their tr…”
BackgroundCOSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites
Cradick, T. J., Qiu, P., Lee, C. M., Fine, E. J., & Bao, G. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.64 · Cited by 408
Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S. (2017) · Nature Communications · doi:10.1038/ncomms14454 · Cited by 387
Smith, C., Gore, A., Yan, W., Abalde-Atristain, L., Li, Z., He, C., Wang, Y., Brodsky, R. A., Zhang, K., Cheng, L., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.06.011 · Cited by 342
Ye, L., Wang, J., Beyer, A. I., Teque, F., Cradick, T. J., Qi, Z., Chang, J. C., Bao, G., Muench, M. O., Yu, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407473111 · Cited by 320
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295 · cited 2×
“Yin et al.127 exploited a new lipid nano-particle to deliver Cas9 mRNA for genome editing; Jiang et al.128 optimized the formula using lipid-like nano-particles (LLNs) for gRNA and Cas9 mRNA delivery.”
MethodHighly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
Gundry, M. C., Brunetti, L., Lin, A., Mayle, A. E., Kitano, A., Wagner, D., Hsu, J. I., Hoegenauer, K. A., Rooney, C. M., Goodell, M. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.092 · Cited by 265 · cited 2×
“Gundry et al.(108) remarkably enhanced the genome-editing efficiency of CRISP/Cas9 in human HSCs using purified gRNA and Cas9 nuclease.”
De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3480 · Cited by 258
Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq
Kim, D., Kim, S., Kim, S., Park, J., & Kim, J.-S. (2016) · Genome Research · doi:10.1101/gr.199588.115 · Cited by 208 · cited 2×
“Some studies have shown that shorter gRNAs can reduce the occurrence of offtarget by reducing their mispairing with the targeted genome, but the indels of on-target will also decrease accordingly, because binding of shorter gRNAs to the targeted genome is not as stable as that of longer ones.(82,83)”
BackgroundSuzuki, K., Yu, C., Qu, J., Li, M., Yao, X., Yuan, T., Goebl, A., Tang, S., Ren, R., Aizawa, E., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.06.016 · Cited by 169
TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype
Fessler, E., Drost, J., van Hooff, S. R., Linnekamp, J. F., Wang, X., Jansen, M., De Sousa E Melo, F., Prasetyanti, P. R., IJspeert, J. E., Franitza, M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606184 · Cited by 159 · cited 2×
“Fessler et al.(53) generated BRAF mutant organoids to explore the function of transforming growth factor b (TGF-b) in”
BackgroundTargeted Genome Modifications Using Integrase-deficient Lentiviral Vectors
Cornu, T. I., & Cathomen, T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300345 · Cited by 105 · cited 1×
“Uncontrolled gene mutations introduced by random integrations are not desired, while integrase-defective lentivirus shows a lower infection efficiency and gene expression level than the normal lentivirus.(135)”
Background
Cited by
Genetic heterogeneity in Leigh syndrome: Highlighting treatable and novel genetic causes
Lee, J. S., Yoo, T., Lee, M., Lee, Y., Jeon, E., Kim, S. Y., Lim, B. C., Kim, K. J., Choi, M., & Chae, J. (2020) · Clinical Genetics · doi:10.1111/cge.13713 · Cited by 92
De Masi, C., Spitalieri, P., Murdocca, M., Novelli, G., & Sangiuolo, F. (2020) · Human Genomics · doi:10.1186/s40246-020-00276-2 · Cited by 91
Process for an efficient lentiviral cell transduction
Pirona, A. C., Oktriani, R., Boettcher, M., & Hoheisel, J. D. (2020) · Biology Methods and Protocols · doi:10.1093/biomethods/bpaa005 · Cited by 31
“Particularly the latter have an enormous impact on genome engineering as they facilitate highly accurate genetic as well as epigenetic modifications and allow to obtain engineered cell lines or animal models in a relatively short time frame compared to alternative approaches [1–3], hence rapidly moving towards clinica…”
Background
Metadata
- Authors
- Zhang, Z., Zhang, Y., Gao, F., Han, S., Cheah, K. S., Tse, H.-F., & Lian, Q.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 9
- Pages
- 230-241
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2761178778
- Cited by
- 114
- References
- 59
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.